Yanke Liang

Title: Yanke Liang: Innovator in Targeted Degradation of RET

Introduction

Yanke Liang is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that target the RET protein, which is implicated in various cancers.

Latest Patents

Yanke Liang holds a patent for "Compounds for targeted degradation of RET." This patent describes compounds of Formula (I) that act as protein degradation inducing moieties for the proto-oncogene tyrosine-protein kinase receptor (RET). These compounds can be utilized to treat disorders mediated by the RET protein, including cancers and tumors. He has 1 patent to his name.

Career Highlights

Yanke Liang is currently associated with C4 Therapeutics, Inc., where he continues to innovate in the field of targeted therapies. His work focuses on developing novel approaches to combat diseases driven by aberrant protein functions.

Collaborations

Some of his notable coworkers include James A. Henderson and Christopher G. Nasveschuk. Their collaborative efforts contribute to advancing research and development in targeted protein degradation.

Conclusion

Yanke Liang's work in the targeted degradation of RET represents a significant advancement in cancer treatment. His innovative compounds hold promise for improving therapeutic outcomes for patients affected by RET-mediated disorders.